Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $1.87 Million - $4.22 Million
40,400 New
40,400 $1.97 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $216,388 - $568,700
-9,400 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $167,226 - $225,600
9,400
9,400 $226,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.